The Chemours Stock Forecast, Price & News

$31.14
-0.42 (-1.33 %)
(As of 09/16/2021 03:02 PM ET)
Add
Compare
Today's Range
$30.79
$31.41
50-Day Range
$30.88
$34.88
52-Week Range
$19.36
$38.87
Volume13,377 shs
Average Volume1.27 million shs
Market Capitalization$5.14 billion
P/E Ratio20.35
Dividend Yield3.23%
Beta2.14
30 days | 90 days | 365 days | Advanced Chart
Receive CC News and Ratings via Email

Sign-up to receive the latest news and ratings for The Chemours and its competitors with MarketBeat's FREE daily newsletter.


The Chemours logo

About The Chemours

The Chemours Co. is a holding company that engages in the provision of performance chemicals. The firm deliver solutions, which include a range of industrial and chemicals products for markets, including coatings, plastics, refrigeration and air conditioning, transportation, semiconductor and consumer electronics, general industrial, mining, and oil & gas. It operates through the following segments: Titanium Technologies, Thermal & Specialized Solutions, Advanced Performance Materials, and Chemical Solutions. The Titanium Technologies segment engages in manufacturing of titanium dioxide pigment. The Thermal & Specialized Solutions segment is a provider of refrigerants, propellants, blowing agents, and specialty solvents. The Advanced Performance Materials segment is a provider of polymers and advanced materials that deliver attributes, including chemical inertness, thermal stability, low friction, weather and corrosion resistance, extreme temperature stability, and di-electric properties. The Chemical Solutions segment with its Mining Solutions & Performance Chemicals and Intermediates engages in businesses that produce industrial chemicals used in applications by customers, which

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

2.83 out of 5 stars

Basic Materials Sector

16th out of 223 stocks

Chemicals & Allied Products Industry

3rd out of 20 stocks

Analyst Opinion: 2.4Community Rank: 4.3Dividend Strength: 2.5Insider Behavior: 2.5Valuation: 2.5 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











The Chemours (NYSE:CC) Frequently Asked Questions

Is The Chemours a buy right now?

9 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for The Chemours in the last twelve months. There are currently 2 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" The Chemours stock.
View analyst ratings for The Chemours
or view top-rated stocks.

What stocks does MarketBeat like better than The Chemours?

Wall Street analysts have given The Chemours a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but The Chemours wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is The Chemours' next earnings date?

The Chemours is scheduled to release its next quarterly earnings announcement on Tuesday, November 2nd 2021.
View our earnings forecast for The Chemours
.

How were The Chemours' earnings last quarter?

The Chemours Company (NYSE:CC) posted its earnings results on Thursday, July, 29th. The specialty chemicals company reported $1.20 earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of $0.89 by $0.31. The specialty chemicals company earned $1.66 billion during the quarter, compared to analyst estimates of $1.51 billion. The Chemours had a trailing twelve-month return on equity of 61.31% and a net margin of 4.57%.
View The Chemours' earnings history
.

How has The Chemours' stock been impacted by Coronavirus (COVID-19)?

The Chemours' stock was trading at $10.66 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CC stock has increased by 191.9% and is now trading at $31.12.
View which stocks have been most impacted by COVID-19
.

How often does The Chemours pay dividends? What is the dividend yield for The Chemours?

The Chemours declared a quarterly dividend on Wednesday, July 28th. Shareholders of record on Monday, August 16th will be given a dividend of $0.25 per share on Wednesday, September 15th. This represents a $1.00 annualized dividend and a yield of 3.21%. The ex-dividend date of this dividend is Friday, August 13th.
View The Chemours' dividend history
.

Is The Chemours a good dividend stock?

The Chemours pays an annual dividend of $1.00 per share and currently has a dividend yield of 3.23%. The dividend payout ratio of The Chemours is 50.51%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, The Chemours will have a dividend payout ratio of 25.19% next year. This indicates that The Chemours will be able to sustain or increase its dividend.
View The Chemours' dividend history.

What guidance has The Chemours issued on next quarter's earnings?

The Chemours issued an update on its FY 2021 earnings guidance on Thursday, August, 5th. The company provided earnings per share guidance of $3.560-$3.560 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $3.560. The company issued revenue guidance of -.

What price target have analysts set for CC?

9 Wall Street analysts have issued 12-month price targets for The Chemours' stock. Their forecasts range from $28.00 to $48.00. On average, they expect The Chemours' stock price to reach $37.78 in the next twelve months. This suggests a possible upside of 21.4% from the stock's current price.
View analysts' price targets for The Chemours
or view top-rated stocks among Wall Street analysts.

Who are The Chemours' key executives?

The Chemours' management team includes the following people:
  • Mark E. Newman, President, CEO, COO, Director & Senior VP
  • Sameer Ralhan, Chief Financial Officer & Senior Vice President
  • Randal King, VP-Technology & Advanced Performance Materials
  • David C. Shelton, Secretary, Senior Vice President & General Counsel
  • Matthew S. Abbott, Vice President & Controller

What is Mark Vergnano's approval rating as The Chemours' CEO?

106 employees have rated The Chemours CEO Mark Vergnano on Glassdoor.com. Mark Vergnano has an approval rating of 85% among The Chemours' employees.

Who are some of The Chemours' key competitors?

What other stocks do shareholders of The Chemours own?

Based on aggregate information from My MarketBeat watchlists, some companies that other The Chemours investors own include AT&T (T), Pfizer (PFE), DuPont de Nemours (DD), NVIDIA (NVDA), Cisco Systems (CSCO), Micron Technology (MU), Intel (INTC), AbbVie (ABBV), CVS Health (CVS) and Energy Transfer (ET).

What is The Chemours' stock symbol?

The Chemours trades on the New York Stock Exchange (NYSE) under the ticker symbol "CC."

Who are The Chemours' major shareholders?

The Chemours' stock is owned by a number of institutional and retail investors. Top institutional shareholders include FMR LLC (12.13%), Vanguard Group Inc. (9.67%), BlackRock Inc. (8.34%), State Street Corp (2.62%), Allianz Asset Management GmbH (2.57%) and LSV Asset Management (2.31%). Company insiders that own The Chemours stock include Alvenia Scarborough, David C Shelton, Denise Dignam, E Bryan Snell, Edwin C Sparks, Mark Newman, Mark P Vergnano, Matthew S Abbott, Richard H Brown and Sameer Ralhan.
View institutional ownership trends for The Chemours
.

Which institutional investors are selling The Chemours stock?

CC stock was sold by a variety of institutional investors in the last quarter, including Sandler Capital Management, AQR Capital Management LLC, BlackRock Inc., Wells Fargo & Company MN, Miller Value Partners LLC, Panagora Asset Management Inc., Russell Investments Group Ltd., and Citadel Advisors LLC. Company insiders that have sold The Chemours company stock in the last year include Alvenia Scarborough, David C Shelton, Denise Dignam, Edwin C Sparks, Mark Newman, Mark P Vergnano, Matthew S Abbott, and Sameer Ralhan.
View insider buying and selling activity for The Chemours
or view top insider-selling stocks.

Which institutional investors are buying The Chemours stock?

CC stock was bought by a variety of institutional investors in the last quarter, including American Century Companies Inc., Allianz Asset Management GmbH, Morgan Stanley, Morgan Stanley, FMR LLC, First Trust Advisors LP, Mackenzie Financial Corp, and State Street Corp. Company insiders that have bought The Chemours stock in the last two years include E Bryan Snell, Mark Newman, and Richard H Brown.
View insider buying and selling activity for The Chemours
or or view top insider-buying stocks.

How do I buy shares of The Chemours?

Shares of CC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is The Chemours' stock price today?

One share of CC stock can currently be purchased for approximately $31.12.

How much money does The Chemours make?

The Chemours has a market capitalization of $5.14 billion and generates $4.97 billion in revenue each year. The specialty chemicals company earns $219 million in net income (profit) each year or $1.98 on an earnings per share basis.

How many employees does The Chemours have?

The Chemours employs 6,500 workers across the globe.

What is The Chemours' official website?

The official website for The Chemours is www.chemours.com.

Where are The Chemours' headquarters?

The Chemours is headquartered at 1007 MARKET STREET, WILMINGTON DE, 19801.

How can I contact The Chemours?

The Chemours' mailing address is 1007 MARKET STREET, WILMINGTON DE, 19801. The specialty chemicals company can be reached via phone at (302) 773-1000 or via email at [email protected]


This page was last updated on 9/16/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.